Antares Pharma (Antares Pharma) LT-Debt-to-Total-Asset : 0.09 (As of Mar. 2022)

View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Antares Pharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2022 was 0.09.

Antares Pharma's long-term debt to total assets ratio increased from Mar. 2021 (0.09) to Mar. 2022 (0.09). It may suggest that Antares Pharma is progressively becoming more dependent on debt to grow their business.

Antares Pharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Antares Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma LT-Debt-to-Total-Asset Chart

Antares Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.33

0.25

0.35

0.14

0.09

Antares Pharma Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.04	0.11	0.09	0.09

Antares Pharma LT-Debt-to-Total-Asset Calculation

Antares Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )	/	Total Assets (A: Dec. 2021 )
	=	22.817	/	257.505
	=	0.09

Antares Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2022 is calculated as

LT Debt to Total Assets (Q: Mar. 2022 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2022 )	/	Total Assets (Q: Mar. 2022 )
	=	22.954	/	255.658
	=	0.09

Antares Pharma (NAS:ATRS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Antares Pharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Antares Pharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Antares Pharma (Antares Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Princeton South, Suite 300, Ewing, NJ, USA, 08628

Website

https://www.antarespharma.com

Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.

Executives

Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart	director	C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson	officer: See Remarks	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell	officer: Executive Vice President & CFO	C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity	director
Roche Robert P Jr	director	41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob	director	C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham	officer: See Remarks	315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth	director
Robert F Apple	director, officer: President & CEO	C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson	director
Jacques Gonella	director	C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi	officer: EVP, Chief Medical Officer	106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn	officer: VP/Controller & Interim CFO	C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447